Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): Outcomes in subgroups and toxicity update

T. K. Choueiri,M. Eto,E. Kopyltsov,S. Y. Rha,C. G. Porta,R. Motzer,V. Gruenwald,T. E. Hutson,M. J. Mendez-Vidal,S-H. Hong,E. Winquist,J. C. H. Goh,P. Maroto,T. Buchler,T. Takagi,K. Rodriguez-Lopez,D. Xing,A. D. Smith,T. Powles

ANNALS OF ONCOLOGY（2021）

Cited 22|Views8

No score

Abstract

In the phase III CLEAR trial, lenvatinib (L) + pembrolizumab (P) demonstrated significant improvement in PFS (HR 0.39; 95% CI 0.32, 0.49; P<0.001), OS (HR 0.66; 95% CI 0.49, 0.88; P=0.005), and ORR (odds ratio 4.35; 95% CI 3.16, 5.97) vs sunitinib (S) for patients (pts) with aRCC. Here we report efficacy results for L + P vs S in distinct subgroups of pts and provide updated toxicity data.

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined